FXall IPO underwriters initiate research coverage

The next step in FXall’s life as a public company was taken last week, with several of the investment banks which underwrote FXall’s IPO last month coming out with investment research on the company.

None of the analysts now covering FXall had much original to say, each coming out with either a $16 or $17 share price “target” for FXall. The investment banks which rated FXall “Neutral” (Goldman, Citi and JP Morgan) basically said that near-term upside is limited, citing the rise in FXall’s share price since IPO for the so-so rating. FXall shares are up 27% (to $15.24) from its IPO price of $12.

Although reforms of the IPO process in the U.S. last decade were supposed to separate the underwriting and research functions – that is, underwriters are not allowed to promise research coverage (and certainly not “positive” research coverage) in order to secure a spot in the underwriting group – it is not really surprising that the Wall Street firms which initiated research were all in FXall’s underwriting group, and all had a “target price” for FXall shares well above the IPO price.

Over the next few days we would expect the other underwriters, including lead-manager BofA Merrill Lynch, to also come out with research coverage. Stay tuned….

Read Also:

LeapRate is an independent research and advisory firm, specialized in covering the world of Forex trading. We are followed by hundreds of thousands of traders, investors and other FX industry participants via our website, Facebook, Twitter, LinkedIn, RSS and Email Newsletter. Copyright © All rights reserved Finaffiliates Limited Website:
https://finaffiliates.com CEO: Jason Hopgood Company number: 14540579 VAT identification number: GB 431522433

Location: Finaffiliates Limited, Lawrence House, 5 St. Andrews Hill, Norwich NR2 1AD, United Kingdom
Email: [email protected]

SUBSCRIBE TO OUR NEWSLETTER

IMPORTANT DISCLAIMERS

Foreign exchange trading comes with high level of risk. Before investing in foreign exchange, carefully consider your level of experience and risk appetite. CFDs are complex instruments and bring high risk of losing money because of the leverage they provide. No information or opinion contained on this site should be taken as investment advice, personal recommendation, or an offer of, or solicitation to buy or sell, any financial instruments. Past performance should not be considered evidence or guarantee for future performance. Between 74 and 89% of retail investors accounts lose money.